FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788006508> ?p ?o ?g. }

• W2788006508 endingPage "12" @default.
• W2788006508 startingPage "1" @default.
• W2788006508 abstract "Malaria is a disease caused by protozoans transmitted to humans by infected female Anopheles mosquitoes. According to the WHO report of 2015, there were 214 million cases of malaria with 438,000 deaths worldwide. Ninety percent of world’s malaria cases occur in Africa, where the disease is recognized as a serious impediment to economic and social development. Despite advancement in malaria research, the disease continues to be a global problem, especially in developing countries. Currently, there is no effective vaccine for malaria control. In addition, although there are effective drugs for treatment of malaria, this could be lost to the drug resistance in different Plasmodium species. The most lethal form is caused by P. falciparum which has developed resistance to many chemotherapeutic agents and possibly to the current drugs of choice. Reducing the impact of malaria is a key to achieving the sustainable development goals which are geared toward combating the disease. Covalent bitherapy is a rational and logical way of drug design which entails joining a couple of molecules with individual intrinsic action into a unique agent, hence packaging dual activity into one hybrid. This suggests the need to develop new antimalarial drugs that are effective against malaria parasites based on the new mode of action, molecular targets, and chemical structures. In silico studies have shown that sarcosine is able to bind to unique plasmodia proteins ( P. falciparum ATCase), whereas aniline can be a ligand to target protein (enoyl acyl carrier protein reductase), hence suppressing the progression of the disease. The main objective of this study was to synthesize and determine the efficacy and safety of antiplasmodial hybrid drug comprising the sarcosine and aniline derivative for management of plasmodial infections. The hybrid drug was synthesized by adding thionyl chloride to sarcosine to form acyl chloride which was then added to aniline to form sarcosine-aniline hybrid molecule. The IC50 of sarcosine-aniline hybrid was 44.80 ± 4.70 ng/ml compared with that of aniline derivative which was 22.86 ± 1.26 ng/ml. The IC50 of control drugs was 2.63 ± 0.38 ng/ml and 5.69 ± 0.39 ng/ml for artesunate and chloroquine, respectively. There was a significant difference between IC50 of sarcosine-aniline hybrid and aniline derivative (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mrow><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math>). There was also a significant difference between sarcosine-aniline hybrid and standard drugs used to treat malaria including artesunate and chloroquine (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M2><mml:mrow><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math>). The ED50 of sarcosine-aniline hybrid drug was 6.49 mg/kg compared with that of aniline derivative which was 3.61 mg/kg. The ED50 of control drugs was 3.56 mg/kg, 2.94 mg/kg, and 1.78 mg/kg for artesunate-aniline hybrid, artesunate, and chloroquine, respectively. There was a significant difference (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M3><mml:mrow><mml:mi>p</mml:mi><mml:mo><</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math>) between ED50 of sarcosine-aniline hybrid and both controls such as aniline derivative, artesunate, artesunate-aniline hybrid, and chloroquine. Cytotoxicity results revealed that sarcosine-aniline hybrid was safe to vero cells with a CC50 of 50.18 ± 3.53 μ g/ml. Sarcosine-aniline hybrid was significantly less toxic compared with artesunate, chloroquine, and doxorubicin. Sarcosine-aniline hybrid was efficacious and safe to mice. Therefore, covalent bitherapy should be used in drug development for drug resistance mitigation." @default.
• W2788006508 created "2018-03-06" @default.
• W2788006508 creator A5008667199 @default.
• W2788006508 creator A5012433995 @default.
• W2788006508 creator A5042404677 @default.
• W2788006508 creator A5076631236 @default.
• W2788006508 creator A5082515443 @default.
• W2788006508 date "2020-04-09" @default.
• W2788006508 modified "2023-09-25" @default.
• W2788006508 title "Chemical Synthesis, Efficacy, and Safety of Antimalarial Hybrid Drug Comprising of Sarcosine and Aniline Pharmacophores as Scaffolds" @default.
• W2788006508 cites W1543790510 @default.
• W2788006508 cites W1771852563 @default.
• W2788006508 cites W1965665318 @default.
• W2788006508 cites W1970192765 @default.
• W2788006508 cites W1979343488 @default.
• W2788006508 cites W1998756721 @default.
• W2788006508 cites W2009596876 @default.
• W2788006508 cites W2011698098 @default.
• W2788006508 cites W2026009812 @default.
• W2788006508 cites W2031109860 @default.
• W2788006508 cites W2033634323 @default.
• W2788006508 cites W2035430020 @default.
• W2788006508 cites W2067428749 @default.
• W2788006508 cites W2081797133 @default.
• W2788006508 cites W2105668259 @default.
• W2788006508 cites W2114918609 @default.
• W2788006508 cites W2120413842 @default.
• W2788006508 cites W2121836743 @default.
• W2788006508 cites W2123876486 @default.
• W2788006508 cites W2153091748 @default.
• W2788006508 cites W2154616221 @default.
• W2788006508 cites W2154949059 @default.
• W2788006508 cites W2156295588 @default.
• W2788006508 cites W2168428623 @default.
• W2788006508 cites W2294626988 @default.
• W2788006508 cites W4293049708 @default.
• W2788006508 doi "https://doi.org/10.1155/2020/1643015" @default.
• W2788006508 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7171691" @default.
• W2788006508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32328112" @default.
• W2788006508 hasPublicationYear "2020" @default.
• W2788006508 type Work @default.
• W2788006508 sameAs 2788006508 @default.
• W2788006508 citedByCount "2" @default.
• W2788006508 countsByYear W27880065082021 @default.
• W2788006508 crossrefType "journal-article" @default.
• W2788006508 hasAuthorship W2788006508A5008667199 @default.
• W2788006508 hasAuthorship W2788006508A5012433995 @default.
• W2788006508 hasAuthorship W2788006508A5042404677 @default.
• W2788006508 hasAuthorship W2788006508A5076631236 @default.
• W2788006508 hasAuthorship W2788006508A5082515443 @default.
• W2788006508 hasBestOaLocation W27880065081 @default.
• W2788006508 hasConcept C114851261 @default.
• W2788006508 hasConcept C142724271 @default.
• W2788006508 hasConcept C203014093 @default.
• W2788006508 hasConcept C2778048844 @default.
• W2788006508 hasConcept C2778371730 @default.
• W2788006508 hasConcept C2779134260 @default.
• W2788006508 hasConcept C2780035454 @default.
• W2788006508 hasConcept C2908859342 @default.
• W2788006508 hasConcept C56173144 @default.
• W2788006508 hasConcept C60644358 @default.
• W2788006508 hasConcept C71924100 @default.
• W2788006508 hasConcept C86803240 @default.
• W2788006508 hasConcept C89423630 @default.
• W2788006508 hasConcept C98274493 @default.
• W2788006508 hasConceptScore W2788006508C114851261 @default.
• W2788006508 hasConceptScore W2788006508C142724271 @default.
• W2788006508 hasConceptScore W2788006508C203014093 @default.
• W2788006508 hasConceptScore W2788006508C2778048844 @default.
• W2788006508 hasConceptScore W2788006508C2778371730 @default.
• W2788006508 hasConceptScore W2788006508C2779134260 @default.
• W2788006508 hasConceptScore W2788006508C2780035454 @default.
• W2788006508 hasConceptScore W2788006508C2908859342 @default.
• W2788006508 hasConceptScore W2788006508C56173144 @default.
• W2788006508 hasConceptScore W2788006508C60644358 @default.
• W2788006508 hasConceptScore W2788006508C71924100 @default.
• W2788006508 hasConceptScore W2788006508C86803240 @default.
• W2788006508 hasConceptScore W2788006508C89423630 @default.
• W2788006508 hasConceptScore W2788006508C98274493 @default.
• W2788006508 hasLocation W27880065081 @default.
• W2788006508 hasLocation W27880065082 @default.
• W2788006508 hasLocation W27880065083 @default.
• W2788006508 hasLocation W27880065084 @default.
• W2788006508 hasOpenAccess W2788006508 @default.
• W2788006508 hasPrimaryLocation W27880065081 @default.
• W2788006508 hasRelatedWork W1073305058 @default.
• W2788006508 hasRelatedWork W2078415706 @default.
• W2788006508 hasRelatedWork W2089765100 @default.
• W2788006508 hasRelatedWork W2114399685 @default.
• W2788006508 hasRelatedWork W2412034129 @default.
• W2788006508 hasRelatedWork W2416097351 @default.
• W2788006508 hasRelatedWork W2509858822 @default.
• W2788006508 hasRelatedWork W2913326054 @default.
• W2788006508 hasRelatedWork W3168117672 @default.
• W2788006508 hasRelatedWork W3199265487 @default.
• W2788006508 hasVolume "2020" @default.
• W2788006508 isParatext "false" @default.
• W2788006508 isRetracted "false" @default.

• next